AIG Hospitals to Launch ₹800 Crore Oncology Centre with South-East Asia’s First Dynamic ARC Proton Therapy

Qiagen Secures FDA Clearance for QIAstat-Dx Gastrointestinal Panel

Ovation.io Launches Groundbreaking GLP-1 Research Dataset to Advance Precision Medicine

Kotak Invests ₹940 Crore in Neuberg Diagnostics to Drive Expansion and IPO Preparation

NICE Recommends Olaparib for BRCA-Mutated Advanced Breast Cancer

SOPHiA GENETICS and Platomics Collaborate to Streamline IVDR Compliance for Clinical Labs

India Unveils Genome Sequencing Data of 10,000 Individuals: A Milestone in Biotechnology Research

Ambry Genetics Advances BRCA2 Variant Classification with CRISPR-Based Study Published in *Nature*

Geneoscopy Secures $105M Series C Funding to Advance Colorectal Cancer Screening

Vertex and Orna Partner to Develop In Vivo Gene Therapies for Blood Disorders

FDA Grants Priority Review to Dizal’s Sunvozertinib for EGFR Exon20ins NSCLC

MD Anderson and Myriad Genetics Forge Strategic Alliance to Advance MRD Testing in Cancer Care

Pillar Biosciences Partners with MSK to Enhance Precision Oncology with OncoKB™ Integration

CytoMed and SunAct Partner to Advance Allogeneic Gamma Delta T Cell Therapy in India

China’s NMPA Approves Astellas’ Zolbetuximab for Advanced Gastric and GEJ Cancer

Home
/
update
/
details

Dyno Therapeutics Expands Collaboration with Roche to Develop Next-Generation Gene Therapies for Neurological Diseases

NextEdge Admin

25 Oct 2024

2 min 19 sec

artificial intelligence,adeno-associated virus,Roche

Dyno Therapeutics, Inc., a genetic technologies company leveraging artificial intelligence (AI) to enhance in vivo gene delivery, announced a new collaboration with Roche to develop next-generation adeno-associated virus (AAV) vectors for gene therapies targeting neurological diseases. This partnership builds on their previous collaboration, initiated in October 2020, which focused on neurological and liver-directed therapies.

Under the agreement, Dyno will design novel AAV capsids with enhanced delivery properties, including improved tissue targeting, immune evasion, and manufacturability, utilizing its proprietary Low-Shot Efficient Accelerated Performance (LEAPSM) technology. LEAPSM enables billions of in vivo sequence-function measurements monthly, accelerating the optimization of AAV capsids. Roche will validate these capsids and lead preclinical, clinical, and commercialization efforts for multiple neurological gene therapy candidates.

The agreement provides Dyno with $50 million upfront, with additional payments throughout the research phase. Potential preclinical, clinical, and sales milestones could exceed $1 billion, complemented by royalties on future product sales.

Dyno’s CEO, Eric Kelsic, Ph.D., emphasized the significance of the collaboration in advancing gene delivery solutions for difficult-to-treat neurological diseases. He highlighted how Dyno’s AI-powered platform and extensive in vivo data collection aim to solve key challenges in gene therapy, bringing the field closer to delivering safe and effective treatments to more patients. Boris L. Zaïtra, Head of Roche Corporate Business Development, expressed confidence in expanding the partnership, noting that combined efforts with Dyno will enable significant progress in treating complex neurological conditions.